-+ 0.00%
-+ 0.00%
-+ 0.00%
Novo Nordisk's Frehemgo Wins Approval for Haemophilia A in Europe
Share
Listen to the news
12:11 AM EST, 11/15/2026 (MT Newswires) -- Novo Nordisk's (NOVO-B.CO) Frehemgo received marketing authorization from the European Commission for haemophilia A in adults and children, according to a Nov. 13 release. Generically known as denecimig, the drug was approved for once-monthly, once-every-two-weeks, or once-weekly dosing using a single-use pre-filled pen to prevent or lower the frequency of bleeding episodes. The decision was supported by the Frontier clinical trial program, in which denecimig significantly cut annualized bleeding rates compared with prior clotting factor prophylaxis and on-demand treatment in people with haemophilia A, with or without inhibitors. The Danish pharmaceutical company will roll out Frehemgo in the first European countries in the year ahead. The treatment also has clearance in Saudi Arabia and is under review in the US.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending